# IMNN catalysts: Imunon, Inc. PDUFA dates and FDA events

Canonical: https://sec-api.dev/companies/imnn/catalysts

> Imunon, Inc. (IMNN) has no upcoming catalysts in this calendar. The latest recorded is the Imunon, Inc. earnings report, November 12, 2026.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: exact day, quarter only, half-year only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Company

| Field | Value |
| --- | --- |
| Name | Imunon, Inc. |
| Ticker | IMNN (Nasdaq) |
| SEC CIK | 749647 |
| SIC | 2834 |
| SEC filings | https://sec-api.dev/companies/imnn |

## Cash runway

Cash $4.0M as of 2026-09-30; quarterly burn $3.2M; about 3.8 months of runway at that rate (XBRL company facts, accession 0001493152-26-051203).

## Catalysts

| Date | Event | Ticker | Indication | Status | Source sentence |
| --- | --- | --- | --- | --- | --- |
| July 30, 2024 | [Imunon, Inc. topline data readout](https://sec-api.dev/companies/imnn/catalysts) | IMNN |  | completed, positive | "July 30, 2024, the Company announced positive topline results from the Phase I/II OVATION 2 Study." ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/749647/000149315226051203/form10-q.htm)) |
| July 30, 2024 | [Imunon, Inc. topline data readout](https://sec-api.dev/companies/imnn/catalysts) | IMNN |  | completed, positive | "July 30, 2024, the Company announced positive topline results from the Phase II OVATION 2 Study." ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/749647/000149315225022120/form10-q.htm)) |
| Q1 2025 | [IMNN-001 trial start](https://sec-api.dev/pdufa/imnn-001) | IMNN |  | scheduled | "As we look forward to an exciting year ahead, we are preparing to initiate a Phase 3 pivotal study of IMNN-001 in the first quarter of 2025."" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/749647/000149315225008457/ex99-1.htm)) |
| 1H 2025 | [IMNN-101 topline data readout](https://sec-api.dev/pdufa/imnn-101) | IMNN |  | scheduled | "Topline safety and immunogenicity data are anticipated in the first half of 2025." ([SEC Form 10-K](https://www.sec.gov/Archives/edgar/data/749647/000149315225008460/form10-k.htm)) |
| February 27, 2025 | [Imunon, Inc. earnings report](https://sec-api.dev/companies/imnn/catalysts) | IMNN |  | completed | "Reports 2024 Financial Results and Provides Business Update Highlighting Significant Progress Towards the Initiation of a Pivotal Phase" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/749647/000149315225008457/ex99-1.htm)) |
| May 12, 2025 | [Imunon, Inc. earnings report](https://sec-api.dev/companies/imnn/catalysts) | IMNN |  | completed | "Reports First Quarter 2025 Financial Results and Provides Business Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/749647/000164117225009570/ex99-1.htm)) |
| August 5, 2025 | [Imunon, Inc. earnings report](https://sec-api.dev/companies/imnn/catalysts) | IMNN |  | completed | "Reports Second Quarter 2025 Financial Results and" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/749647/000149315225011597/ex99-1.htm)) |
| November 13, 2025 | [Imunon, Inc. earnings report](https://sec-api.dev/companies/imnn/catalysts) | IMNN |  | completed | "Reports Third Quarter 2025 Financial Results and" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/749647/000149315225022118/ex99-1.htm)) |
| March 31, 2026 | [Imunon, Inc. earnings report](https://sec-api.dev/companies/imnn/catalysts) | IMNN |  | completed | "Reports 2025 Financial Results and Provides Business Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/749647/000149315226013816/ex99-1.htm)) |
| May 12, 2026 | [Imunon, Inc. earnings report](https://sec-api.dev/companies/imnn/catalysts) | IMNN |  | completed | "Reports First Quarter 2026 Financial Results and" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/749647/000149315226022401/ex99-1.htm)) |
| August 11, 2026 | [Imunon, Inc. earnings report](https://sec-api.dev/companies/imnn/catalysts) | IMNN |  | completed | "Reports Second Quarter 2026 Financial Results and Provides Business Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/749647/000149315226036985/ex99-1.htm)) |
| November 12, 2026 | [Imunon, Inc. earnings report](https://sec-api.dev/companies/imnn/catalysts) | IMNN |  | completed | "Reports Third Quarter 2026 Financial Results and Provides Business Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/749647/000149315226051202/ex99-1.htm)) |

## Drugs

- [IMNN-001](https://sec-api.dev/pdufa/imnn-001): 
- [IMNN-101](https://sec-api.dev/pdufa/imnn-101): 

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/companies/imnn/catalysts.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "IMNN catalysts: Imunon, Inc. PDUFA dates and FDA events." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/companies/imnn/catalysts

```bibtex
@misc{secapidev_companies_imnn_catalysts_20261116,
  title        = {IMNN catalysts: Imunon, Inc. PDUFA dates and FDA events},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/companies/imnn/catalysts}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_companies_imnn_catalysts_20261116","title":"IMNN catalysts: Imunon, Inc. PDUFA dates and FDA events","publisher":"sec-api.dev","URL":"https://sec-api.dev/companies/imnn/catalysts","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
